Special Issue

Metabolic Dysfunction-Associated Steatotic Disease

Message from the Guest Editor

MAFLD/MASLD, a metabolic disorder characterized by hepatic steatosis overlapping with multiple metabolic disturbances, has gained worldwide recognition due to its escalating global prevalence, now affecting over 30% of the general population, including lean individuals that were previously considered low risk.

Despite progress, key challenges persist: (1) precise non-invasive diagnosis distinguishing between MAFLD and its progressive forms; (2) elucidating the role of gut–liver axis dysbiosis (e.g., Bacteroides overgrowth) and epigenetic modifications in disease progression; and (3) limited biomarkers to predict transition from steatosis to steatohepatitis (NASH).

We invite contributions on the following:
Novel classification using proteomic and metabolomic profiles;
Molecular mechanisms linking metabolism and lipotoxicity to inflammation/fibrosis;
Diagnostic dilemmas beyond the current imaging/biomarker paradigms;
The efficacy of emerging therapies (e.g., GLP-1RAs, FGF21 analogs, nutrition intervention) across disease stages;
Future directions, including Artificial Intelligence applications.

Guest Editor

Dr. Junzhao Ye

Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

Deadline for manuscript submissions

30 March 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).